These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9624250

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment.
    Raaphorst GP, Chabot P, Doja S, Wilkins D, Stewart D, Ng CE.
    Int J Hyperthermia; 1996; 12(2):211-22. PubMed ID: 8926390
    [Abstract] [Full Text] [Related]

  • 23. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
    Blommaert FA, Floot BG, van Dijk-Knijnenburg HC, Berends F, Baan RA, Schornagel JH, den Engelse L, Fichtinger-Schepman AM.
    Chem Biol Interact; 1998 Jan 30; 108(3):209-25. PubMed ID: 9528691
    [Abstract] [Full Text] [Related]

  • 24. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 30; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 25. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA.
    Carcinogenesis; 1996 Dec 30; 17(12):2763-9. PubMed ID: 9006117
    [Abstract] [Full Text] [Related]

  • 26. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.
    Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X.
    Anticancer Drugs; 2005 Oct 30; 16(9):1009-16. PubMed ID: 16162978
    [Abstract] [Full Text] [Related]

  • 27. Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
    Formenti SC, Shrivastava PN, Sapozink M, Jozsef G, Chan KK, Jeffers S, Morrow PC, Muggia FM.
    Int J Radiat Oncol Biol Phys; 1996 Jul 15; 35(5):993-1001. PubMed ID: 8751408
    [Abstract] [Full Text] [Related]

  • 28. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL.
    Cancer Chemother Pharmacol; 1999 Jul 15; 43(2):106-14. PubMed ID: 9923815
    [Abstract] [Full Text] [Related]

  • 29. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC.
    Cancer Res; 1994 Nov 15; 54(22):5911-6. PubMed ID: 7954422
    [Abstract] [Full Text] [Related]

  • 30. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
    De Pooter CM, Van Oosterom AT, Scalliet PG, Maes RA, de Bruijn EA.
    Biochem Pharmacol; 1996 Mar 08; 51(5):629-34. PubMed ID: 8615899
    [Abstract] [Full Text] [Related]

  • 31. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.
    Cancer Chemother Pharmacol; 1997 Mar 08; 39(3):245-53. PubMed ID: 8996528
    [Abstract] [Full Text] [Related]

  • 32. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E.
    Int J Oncol; 2000 Mar 08; 16(3):555-60. PubMed ID: 10675489
    [Abstract] [Full Text] [Related]

  • 33. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
    Leopold KA, Oleson JR, Clarke-Pearson D, Soper J, Berchuck A, Samulski TV, Page RL, Blivin J, Tomberlin JK, Dewhirst MW.
    Int J Radiat Oncol Biol Phys; 1993 Dec 01; 27(5):1245-51. PubMed ID: 8262854
    [Abstract] [Full Text] [Related]

  • 34. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
    Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AM, Shellard SA.
    Eur J Cancer; 1994 Dec 01; 30A(6):832-7. PubMed ID: 7917544
    [Abstract] [Full Text] [Related]

  • 35. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment.
    Raaphorst GP, Doja S, Davis L, Stewart D, Ng CE.
    Cancer Chemother Pharmacol; 1996 Dec 01; 37(6):574-80. PubMed ID: 8612312
    [Abstract] [Full Text] [Related]

  • 36. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.
    Cancer Chemother Pharmacol; 2002 Mar 01; 49(3):201-10. PubMed ID: 11935212
    [Abstract] [Full Text] [Related]

  • 37. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
    Muller M, Chérel M, Dupré PF, Gouard S, Collet M, Classe JM.
    Eur Surg Res; 2011 Mar 01; 46(3):139-47. PubMed ID: 21372578
    [Abstract] [Full Text] [Related]

  • 38. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
    Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, Schellens JH, Begg AC.
    Int J Cancer; 2006 Aug 15; 119(4):750-6. PubMed ID: 16550603
    [Abstract] [Full Text] [Related]

  • 39. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ.
    Clin Cancer Res; 2001 Aug 15; 7(8):2205-12. PubMed ID: 11489793
    [Abstract] [Full Text] [Related]

  • 40. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ, Yunmbam MK, Zhong X, Yu JJ, Mimnaugh EG, Neckers L, Reed E.
    Cell Mol Biol (Noisy-le-grand); 2001 Aug 15; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.